• Vaccine Name: COMVAX
• Target Pathogen: Haemophilus influenzae
• Target Disease: Meningitis
• Product Name: Haemophilus b Conjugate
• Tradename: COMVAX
• Manufacturer: Merck & Co., Inc
• Vaccine Ontology ID: VO_0000028
• CDC CVX code: 51
• Type: Conjugate vaccine
• Status: Licensed
• Location Licensed: USA (License #0002)
• Host Species for Licensed Use: Human
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0000127
  • Description: Description: It is a vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants 6 weeks to 15 months of age born of HBsAg negative mothers.
• Preparation: It is grown in complex fermentation media. It is then purified from the culture broth by purification procedures which include ethanol fractionation, enzyme digestion, phenol extraction and diafiltration (FDA: COMVAX).
• Immunization Route: Intramuscular injection (i.m.)
• Storage: Store vaccine at 2-8°C (36-46*F). Storage above or belew the recommended temperature may reduce potency. DO NOT FREEZE since freezing destroys potency.(Comvax)
• Approved Age for Licensed Use: 2-15 months of age.
• Contraindication: Hypersensitivity to any component of the vaccine.
• Description: Immunization of persons 6 weeks to 15 months of age born to hepatitis B surface antigen (HBsAg) negative mothers.

Human Response

• Vaccination Protocol: COMVAX SHOULD NOT BE USED IN INFANTS YOUNGER THAN 6 WEEKS OF AGE.(Comvax)
• Immune Response: No impairment of immune response to individually tested vaccine antigens
• Side Effects: Injection site reactions as well as systemic complaints occur.
• Efficacy: A protective efficacy of 93% was achieved with an anti-PRP level of >l.O mcg/mL in 60% of vaccines and a GMT of 1.43 mcg/mL one to three months after the second dose.(Comvax)
• Description: It is a vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants 6 weeks to 15 months of age born of HBsAg negative mothers.